Document is current
Any future updates will be listed below
-
Authors
Hsu, Austin http://orcid.org/0000-0002-4361-4358
Duan, Qiming
Day, Daniel S.
Luo, Xin
McMahon, Sarah
Huang, Yu
Feldman, Zachary B.
Jiang, Zhen
Zhang, Tinghu
Liang, Yanke
Alexanian, Michael
Padmanabhan, Arun
Brown, Jonathan D.
Lin, Charles Y. http://orcid.org/0000-0002-9155-090X
Gray, Nathanael S. http://orcid.org/0000-0001-5354-7403
Young, Richard A. http://orcid.org/0000-0001-8855-8647
Bruneau, Benoit G. http://orcid.org/0000-0002-0804-7597
Haldar, Saptarsi M. http://orcid.org/0000-0001-7968-9696
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (HL127240)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (GM123511, T32GM008568)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (U01 CA213333-03)
Tobacco-Related Disease Research Program ((28DT-008)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences
- License Information
-
More Information
Article History
Received: 17 January 2021
Accepted: 13 June 2022
First Online: 27 July 2022
Competing interests
: S.M.H. is an officer, executive and shareholder of Amgen, a scientific founder and shareholder of Tenaya Therapeutics, and serves on the Scientific Advisory Board of the DZHK (German Centre for Cardiovascular Research) of the German Ministry of Health as an uncompensated volunteer. X.L. is an employee and shareholder of Amgen. B.G.B. is a scientific founder and shareholder of Tenaya Therapeutics. R.A.Y. is a founder and shareholder of Syros Pharmaceuticals, Camp4 Therapeutics, Omega Therapeutics, and Dewpoint Therapeutics. N.S.G. is a Scientific Founder, member of the SAB and equity holder in C4 Therapeutics, Syros, Soltego (board member), B2S/Voronoi, Allorion, Lighthorse, Cobroventures, GSK, Larkspur (board member) and Matchpoint. The Gray lab receives research funding from Springworks and Interline. T.Z. is a scientific funder, equity holder and consultant of Matchpoint. The remaining authors declare no competing interests.
